Preceptis Medical Selects AcuityMD for Expansion of Breakthrough In-Office Pediatric Ear Tube Device

October 21, 2025

AcuityMD’s data and insights drive commercial growth of important new option to families seeking alternatives for routine ear tube placement in millions of children.

BOSTON – October 21, 2025 – In recognition of Children’s Health Month, AcuityMD, the AI platform for MedTech, announced that Preceptis Medical has selected its platform to support an expanded market launch of the Hummingbird® Tympanostomy Tube System (TTS). TTS offers a unique approach for pediatric ear tube placement in the office without the need for the operating room or general anesthesia. Preceptis Medical, a medical device company focused on office-based options for pediatric patients, chose AcuityMD for its deep industry expertise, comprehensive market data, and AI-driven insights to guide commercial decision making.

“We are an emerging company focused on growth through expanding patient access, and needed a powerful technology platform that would allow our team to work smarter, faster, and make informed decisions,” said David Carey, CEO of Preceptis Medical. “Our early market release demonstrated strong adoption and the need to further expand our footprint in the market. The platform offers insights on the right physicians to engage, how to hire strategically, set up smarter sales territories, and make better decisions at every step.”

‍

Millions of Children Benefit

Approximately one million children annually will undergo ear tube procedures in the U.S., and by age three, one out of every 15 children will have tubes. Patients usually undergo the procedure in an operating room, which can be costly, have more risk, and be restrictive for many families. Further, both parents and pediatricians want to avoid exposing children to general anesthesia when possible, making the Hummingbird office procedure a simpler and preferred option.

According to Shelagh A. Cofer, M.D., a pediatric otolaryngologist and surgeon at Mayo Clinic in Minnesota who participated in a clinical trial with Preceptis Medical, the Hummingbird TTS is a 'single-pass' tool because it is designed to reduce steps and enable ear tube cases to be performed quickly in the office versus the operating room. “It's a revolutionary step forward for our field," said Dr. Cofer.

Carey concluded, “AcuityMD is the cornerstone of our Hummingbird Catalyst program, where we partner with customers to increase Hummingbird awareness and access in the community. AcuityMD will help us engage with the right surgeons, and create greater awareness amongst payers, pediatricians, and parents about our unique solution.”

‍

‍

About AcuityMD

AcuityMD is the AI platform for MedTech and trusted by more than 400 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.